Paolo A Ascierto

Summary

Publications

  1. pmc Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
    Paolo A Ascierto
    Unit of Medical Oncology and Innovative Therapies, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:196. 2011
  2. pmc Serious haematological toxicity during and after ipilimumab treatment: a case series
    Ester Simeone
    Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G, Pascale, Via Mariano Semmola, 80131 Napoli, Italy
    J Med Case Rep 8:240. 2014
  3. pmc What have we learned from cancer immunotherapy in the last 3 years?
    Paolo A Ascierto
    Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G, Pascale, Via Mariano Semmola, 80131 Naples, Italy
    J Transl Med 12:141. 2014
  4. pmc Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
    Paolo A Ascierto
    Istituto Nazionale Tumori Fondazione G, Pascale, Napoli, Italy
    J Transl Med 12:116. 2014
  5. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
  6. pmc NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug
    Simona Caporali
    Laboratory of Molecular Oncology, Istituto Dermopatico dell Immacolata IRCCS, Rome, Italy
    J Transl Med 10:252. 2012
  7. pmc The cost of unresectable stage III or stage IV melanoma in Italy
    Michele Maio
    Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Strada delle Scotte, 53100, Siena, Italy
    J Exp Clin Cancer Res 31:91. 2012
  8. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
  9. pmc The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
    Paolo A Ascierto
    Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G, Pascale, Napoli, Italy
    J Transl Med 11:54. 2013
  10. pmc Do BRAF inhibitors select for populations with different disease progression kinetics?
    Paolo Antonio Ascierto
    Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Department of Melanoma, Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy
    J Transl Med 11:61. 2013

Detail Information

Publications49

  1. pmc Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
    Paolo A Ascierto
    Unit of Medical Oncology and Innovative Therapies, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:196. 2011
    ....
  2. pmc Serious haematological toxicity during and after ipilimumab treatment: a case series
    Ester Simeone
    Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G, Pascale, Via Mariano Semmola, 80131 Napoli, Italy
    J Med Case Rep 8:240. 2014
    ..Here we describe three patients who developed serious haematological adverse events during or after treatment with ipilimumab...
  3. pmc What have we learned from cancer immunotherapy in the last 3 years?
    Paolo A Ascierto
    Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G, Pascale, Via Mariano Semmola, 80131 Naples, Italy
    J Transl Med 12:141. 2014
    ....
  4. pmc Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
    Paolo A Ascierto
    Istituto Nazionale Tumori Fondazione G, Pascale, Napoli, Italy
    J Transl Med 12:116. 2014
    ..Ipilimumab improves survival in patients with advanced melanoma. The activity and safety of ipilimumab outside of a clinical trial was assessed in an expanded access programme (EAP)...
  5. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
    ..The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune)...
  6. pmc NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug
    Simona Caporali
    Laboratory of Molecular Oncology, Istituto Dermopatico dell Immacolata IRCCS, Rome, Italy
    J Transl Med 10:252. 2012
    ..Here we investigated whether NF-κB is activated by TMZ and whether AKT is involved in this molecular event. We also evaluated the functional consequence of inhibiting NF-κB on tumor cell response to TMZ...
  7. pmc The cost of unresectable stage III or stage IV melanoma in Italy
    Michele Maio
    Medical Oncology and Immunotherapy, Azienda Ospedaliera Universitaria Senese, Istituto Toscano Tumori, Strada delle Scotte, 53100, Siena, Italy
    J Exp Clin Cancer Res 31:91. 2012
    ....
  8. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
    ....
  9. pmc The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
    Paolo A Ascierto
    Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G, Pascale, Napoli, Italy
    J Transl Med 11:54. 2013
    ..The challenge will be to identify the individual immunoprofile of each patient and the consequent choice of optimal therapy or combination of therapies to be used...
  10. pmc Do BRAF inhibitors select for populations with different disease progression kinetics?
    Paolo Antonio Ascierto
    Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Department of Melanoma, Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy
    J Transl Med 11:61. 2013
    ....
  11. pmc Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
    Antonio Daponte
    Department of Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Via Mariano Semmola, 80131, Naples, Italy
    J Transl Med 11:38. 2013
    ..The effect of the addition of fotemustine and/or interferon (IFN) to standard therapy with dacarbazine alone in patients with advanced malignant melanoma was investigated in a multicenter, randomized 2x2 factorial design trial...
  12. doi Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review
    Paolo A Ascierto
    Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale, Naples, Italy
    Crit Rev Oncol Hematol 85:149-61. 2013
    ....
  13. pmc Tumor biobanks in translational medicine
    Gerardo Botti
    Istituto Nazionale Tumori Fondazione G, Pascale, Napoli, Italy
    J Transl Med 10:204. 2012
    ....
  14. pmc Lean oncology: a new model for oncologists
    Vincenzo Montesarchio
    Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G, Pascale, Via Mariano Semmola, 80131, Naples, Italy
    J Transl Med 10:74. 2012
    ..Its main objective is the centrality of the patient...
  15. pmc Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report
    Ester Simeone
    Istituto Nazionale Tumori, Fondazione G, Pascale, Napoli, Italy
    J Med Case Rep 6:131. 2012
    ..abstract:..
  16. pmc Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
    Paolo A Ascierto
    Melanoma, Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G, Pascale, Naples, Italy
    J Transl Med 10:107. 2012
    ..The aim of this analysis was to identify factors that could potentially be used to optimise the order in which ipilimumab and BRAF inhibitors are administered in this patient population...
  17. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  18. pmc The immune score as a new possible approach for the classification of cancer
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, 15 Rue de l Ecole de Medecine F 75006 Paris, France
    J Transl Med 10:1. 2012
    ....
  19. pmc The role of BRAF V600 mutation in melanoma
    Paolo A Ascierto
    Department of Melanoma, Istituto Nazionale Tumori Fondazione G, Pascale, Naples, Italy
    J Transl Med 10:85. 2012
    ....
  20. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
    ....
  21. pmc NF-κB as potential target in the treatment of melanoma
    Gabriele Madonna
    Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione, G, Pascale, Napoli, Italy
    J Transl Med 10:53. 2012
    ..Among these, NFκB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis. Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies...
  22. pmc Main roads to melanoma
    Giuseppe Palmieri
    Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche CNR, Sassari, Italy
    J Transl Med 7:86. 2009
    ..Progression from normal melanocytes to malignant metastatic cells in melanoma patients is the result of a combination of down- or up-regulation of various effectors acting on different molecular pathways...
  23. pmc Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
    Maria Libera Ascierto
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center of Human Immunology, National Institutes of Health, Bethesda, MD, USA
    BMC Cancer 11:451. 2011
    ....
  24. pmc Melanoma: a model for testing new agents in combination therapies
    Paolo A Ascierto
    Unit of Medical Oncology and Innovative Therapy, National Tumor Institute, Naples, Italy
    J Transl Med 8:38. 2010
    ....
  25. pmc The role of spectrophotometry in the diagnosis of melanoma
    Paolo A Ascierto
    National Cancer Institute, Naples, Italy
    BMC Dermatol 10:5. 2010
    ..Spectrophotometry (SPT) could represent a promising technique for the diagnosis of cutaneous melanoma (CM) at earlier stages of the disease. Starting from our experience, we further assessed the role of SPT in CM early detection...
  26. doi Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies
    Paolo A Ascierto
    Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    Semin Oncol 37:508-16. 2010
    ..As new class of drugs in cancer therapy, immunostimulatory mAbs have resulted in redefinition of tumor response criteria and rethinking of the rationale for combining these among each other and with other strategies...
  27. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:32. 2011
    ..Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies...
  28. pmc Combination therapy: the next opportunity and challenge of medicine
    Paolo A Ascierto
    Medical Oncology and Innovative Therapies Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G, Pascale, Napoli, Italy
    J Transl Med 9:115. 2011
    ..After recent successes in the immunotherapy field (Sepuleucel-T, ipilimumab) and the new promising small molecule therapies, cancer should be the next challenge for combination strategies...
  29. pmc Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment
    Paolo A Ascierto
    Unit of Medical Oncology and Innovative Therapy and Melanoma Cooperative Group, National Tumor Institute, Naples, Italy
    J Transl Med 8:76. 2010
    ....
  30. ncbi Update on PEG-interferon α-2b as adjuvant therapy in melanoma
    Rossella Di Trolio
    Unit of Medical Oncology and Innovative Therapy, G Pascale Institute of National Tumor Foundation, Naples, Italy
    Anticancer Res 32:3901-9. 2012
    ..This review, after a short summary of interferon α-2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease...
  31. ncbi Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
    Ester Simeone
    Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, IRCCS, Istituto Nazionale Tumori Fondazione G Pascale, Via Mariano Semmola, 80131, Naples, Italy
    Cancer Immunol Immunother 63:675-83. 2014
    ..Identification of a biomarker that correlates with clinical benefit and potentially provides an early marker of response is an active area of research...
  32. pmc Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
    Giusy Gentilcore
    Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    BMC Cancer 13:17. 2013
    ..We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients' tumour tissues and carrying the BRAFV600D/R mutations...
  33. ncbi Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies
    Paolo A Ascierto
    Pascale NAtional Cancer Institute, Naples, Italy
    J Clin Oncol 23:7660-8. 2005
    ..A novel amino acid-degrading enzyme (arginine deiminase) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) was used to lower plasma arginine in individuals with metastatic melanoma...
  34. ncbi CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type
    Stefania Scala
    Department of Clinical Immunology, National Cancer Institute, G Pascale Foundation, Via Mariano Semmola, 80131, Naples, Italy
    Cancer Immunol Immunother 56:1589-95. 2007
    ..CXCR4, a chemokine receptor, is a prognostic factor in cutaneous melanoma involved in angiogenesis and metastasis formation. The aim of this study was to evaluate the expression of CXCR4 in uveal melanoma...
  35. pmc Increased HOX C13 expression in metastatic melanoma progression
    Monica Cantile
    Pathology Unit, Istituto Nazionale Tumori Fondazione G, Pascale, Via Mariano Semmola, 80131, Naples, Italy
    J Transl Med 10:91. 2012
    ..Among these, Hox C13 is also involved in the expression control of the human keratin genes hHa5 and hHa2, and recently it was identified as a member of human DNA replication complexes...
  36. ncbi Marker utility for combination therapy
    Ester Simeone
    Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy
    Methods Mol Biol 1102:97-115. 2014
    ..Here we review the utility of some potential biomarkers of treatment response in patients with metastatic melanoma. ..
  37. ncbi Human melanoma metastases express functional CXCR4
    Stefania Scala
    Department of Clinical Immunology, National Cancer Institute, G Pascale Foundation, Naples, Italy
    Clin Cancer Res 12:2427-33. 2006
    ..The chemokine receptor CXCR4 was identified as an independent predictor of poor prognosis in primary melanoma. The aim of the study was to investigate the role of CXCR4 in human melanoma metastases...
  38. pmc Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma
    Nicola Mozzillo
    Department of Surgery, National Cancer Institute, Via Mariano Semmola, Naples, Italy
    J Transl Med 10:131. 2012
    ..ECT has been used in palliative management of metastatic melanoma to improve patients' quality of life. This is, to our knowledge, the first application of ECT as neoadjuvant treatment of metastatic subcutaneous melanoma...
  39. doi MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
    Paolo A Ascierto
    National Tumor Institute, Foundation G Pascale, Naples, Italy
    Lancet Oncol 14:249-56. 2013
    ..We aimed to assess the use of MEK162, a small-molecule MEK1/2 inhibitor, in patients with NRAS-mutated or Val600 BRAF-mutated advanced melanoma...
  40. doi Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1
    Ester Simeone
    Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy
    J Immunotoxicol 9:241-7. 2012
    ..that represent the natural evolution of future melanoma therapy...
  41. pmc The role of optical radiations in skin cancer
    Fabrizio Ayala
    Department of Melanoma, National Cancer Institute Pascale Foundation, Via Mariano Semmola, 80131 Naples, Italy
    ISRN Dermatol 2013:842359. 2013
    ..In addition, precautionary measures that discourage exposure to tanning appliances are required, as is legislation to prevent their use during childhood...
  42. pmc Adjuvant therapy of melanoma with interferon: lessons of the past decade
    Paolo A Ascierto
    Unit of Medical Oncology and Innovative Therapy, Melanoma Cooperative Group, National Tumor Institute, Naples, Italy
    J Transl Med 6:62. 2008
    ..Future efforts may well build toward patient-oriented therapy based upon the knowledge of the unique molecular features of this disease and the immune system of each melanoma patient...
  43. doi Novel approaches in melanoma prevention and therapy
    Antonio M Grimaldi
    Unit of Melanoma, Immunotherapy and Innovative Therapies, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale, Via Mariano Semmola, 80131, Naples, Italy
    Cancer Treat Res 159:443-55. 2014
    ..Combination strategies of BRAF inhibitors with ipilimumab, an anti-CTLA-4 antibody, and/or MEK inhibitors or metformin are now under investigation in clinical trials. ..
  44. doi Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types
    Paolo A Ascierto
    Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy
    Clin Cancer Res 19:1009-20. 2013
    ....
  45. ncbi Adjuvant treatment of malignant melanoma: where are we?
    Paolo A Ascierto
    Unit of Clinical Immunology, Melanoma Cooperative Group, National Cancer Institute, Via Mariano Semmola, 80131 Naples, Italy
    Crit Rev Oncol Hematol 57:45-52. 2006
    ..Conversely, considering the improvement of OS as the main target of MM adjuvant therapy, the "wait and watch" attitude remains the only approach to be pursued at present. It is a physician's choice...
  46. doi The role of MEK inhibitors in the treatment of metastatic melanoma
    Antonio M Grimaldi
    Istituto Nazionale Tunori Fondazione G Pascale, Naples, Italy
    Curr Opin Oncol 26:196-203. 2014
    ..The first MEK inhibitor (trametinib) has recently been approved for the treatment of BRAF-mutated metastatic melanoma not previously treated with BRAF inhibitors and several more are in clinical development...
  47. doi EGFR mutational status in penile cancer
    Giuseppe Di Lorenzo
    University Federico II, Genitourinary Cancer Section and Rare Cancer Center, Medical Oncology Division, Napoli, Italy
    Expert Opin Ther Targets 17:501-5. 2013
    ..Clinical data are available on the role of epidermal growth factor receptors (EGFR) inhibitors in PC but no EGFR mutational analysis has been conducted...
  48. doi Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination
    Ignacio Melero
    Department of Oncology, Centro de Investigación Médica Aplicada, Clinica Universidad de Navarra, Pamplona, Spain
    Clin Cancer Res 19:997-1008. 2013
    ..Combinations with other more conventional means of treatment such as radiotherapy, chemotherapy, or cancer vaccines also hold much promise...